United Homes Group stock plunges after Nikki Haley, directors resign
Chief Medical Officer of Mineralys Therapeutics (NASDAQ:MLYS), David Malcom Rodman, sold 10,369 shares of common stock on October 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as the $3.32 billion market cap company trades near its 52-week high of $44.38, having delivered an impressive 252% return year-to-date, according to InvestingPro data. The shares were sold at a weighted-average price of $43.0111, resulting in a total transaction value of $445,982.
The prices for the shares sold ranged from $42.8000 to $43.1950. Following the transaction, Rodman directly owns 71,155 shares of Mineralys Therapeutics .
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 25, 2024. For more detailed analysis and 15 additional key insights about Mineralys Therapeutics, visit InvestingPro.
In other recent news, Mineralys Therapeutics, Inc. has reported positive subgroup data from its Phase 3 Launch-HTN trial, demonstrating significant blood pressure reductions with its aldosterone synthase inhibitor, lorundrostat, across diverse patient populations. This data was shared at the American Heart Association Hypertension Scientific Sessions, highlighting consistent efficacy among high-risk groups, including Black/African American adults and older adults. Meanwhile, the company has successfully completed a $287.5 million public offering, selling over 11 million shares of common stock. Mineralys also announced the completion of enrollment in its Phase 2 EXPLORE-OSA clinical trial, which is evaluating lorundrostat for sleep apnea and hypertension, with results expected in early 2026.
Analyst firms have also been active in their evaluations of Mineralys. H.C. Wainwright reiterated its Buy rating and set a $42 price target, citing the potential of lorundrostat compared to AstraZeneca’s baxdrostat. In contrast, Jefferies raised its price target for Mineralys from $15 to $26, maintaining a Hold rating, following a notable increase in the company’s stock price. These developments indicate a growing interest in Mineralys’ clinical advancements and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.